ZEUS - ZINBRYTA real world use study in Germany
- Conditions
- Relapsing remitting multiple sclerosis (RMS)Nervous System DiseasesMultiple sclerosis
- Registration Number
- ISRCTN11671729
- Lead Sponsor
- Biogen GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Stopped
- Sex
- All
- Target Recruitment
- 1000
1. Ability to understand the purpose of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations
2. Start of daclizumab therapy in accordance with local prescribing information; the decision for the daclizumab therapy must be made before study inclusion; patients can be enrolled until before administration of fourth daclizumab dose - provided baseline data are available
3. Aged at least 18 years at time of enrolment; no upper age limit
1. Missing ability or willingness to give informed consent after information about the study
2. Missing eligibility for participation from physician's point of view
3. Contraindication to treatment with daclizumab or diseases which are contraindicated according to the local prescribing information
4. Concomitant therapy with another disease-modifying MS-therapy
5. Current or planned participation in a clinical interventional study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients who are on treatment with daclizumab at Month 24 after treatment initiation (current therapy is documented at each visit: baseline, 3 months, 6 months, and every 6 months until month 60)
- Secondary Outcome Measures
Name Time Method